RESPIRONICS INC Form 8-K March 10, 2006

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):	March 7, 2006
Date of Report (Date of Earliest Event Reported).	March 7, 2000

Respironics, Inc.

(Exact name of registrant as specified in its charter)

Delaware	000-16723	25-1304989
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employe Identification No
1010 Murry Ridge Lane, Murrysville, Pennsylvania		15668-8525
(Address of principal executive offices)		(Zip Code)
Registrant s telephone number, including a	rea code:	724-387-5200
	Not Applicable	
Former nam	e or former address, if changed since l	ast report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Top of the Form Item 7.01 Regulation FD Disclosure.

On March 7, 2006 Respironics, Inc. ("the Company") issued a press release announcing that John Miclot, President and Chief Executive Officer, will present at the 26th Annual Cowen Health Care Conference in Boston, MA, on Wednesday, March 8, 2006.

Mr. Miclot will be presenting Respironics' vision and strategy for growth in the sleep and respiratory marketplaces. Mr. Miclot will also be discussing the Company's upcoming product launches.

A copy of the press release is attached hereto as Exhibit 99.

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Respironics, Inc.

March 7, 2006 By: Daniel J. Bevevino

Name: Daniel J. Bevevino

Title: Vice President, and Chief Financial and Principal

Accounting Officer

Top of the Form

Exhibit Index

Exhibit No.	Description
99	Press release, dated March 7, 2006, issued by Respironics, Inc.